Fosun Pharma 1H FY26 profit attributable to shareholders rises 19.09% to RMB 1.14 billion; revenue increases 4.75% to RMB 20.44 billion
Regent Pacific returns to profit in H1 FY26, net profit US$544,000
Fosun Pharma unit starts China Phase II trial of COPD drug candidate FXS7553
Fosun Pharma Subsidiary Wins Approval for Pediatric Constipation Drug in China
Fosun International Issues 1H2026 Positive Profit Alert as Core Industries Show Strong Resilience
Fosun expects 1H profit attributable to owners at RMB 1.5 billion-RMB 1.8 billion